CN117529320A - 用于治疗病毒感染的rock2抑制剂 - Google Patents
用于治疗病毒感染的rock2抑制剂 Download PDFInfo
- Publication number
- CN117529320A CN117529320A CN202280030027.8A CN202280030027A CN117529320A CN 117529320 A CN117529320 A CN 117529320A CN 202280030027 A CN202280030027 A CN 202280030027A CN 117529320 A CN117529320 A CN 117529320A
- Authority
- CN
- China
- Prior art keywords
- ring
- group
- membered
- hours
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152260P | 2021-02-22 | 2021-02-22 | |
| US63/152260 | 2021-02-22 | ||
| PCT/US2022/017312 WO2022178420A1 (en) | 2021-02-22 | 2022-02-22 | Rock2 inhibitor for the treatment of viral infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117529320A true CN117529320A (zh) | 2024-02-06 |
Family
ID=82931820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280030027.8A Pending CN117529320A (zh) | 2021-02-22 | 2022-02-22 | 用于治疗病毒感染的rock2抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240165116A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4301132A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507414A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240009918A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117529320A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022224669A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3209240A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022178420A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202327608A (zh) * | 2021-09-17 | 2023-07-16 | 北京泰德製藥股份有限公司 | 治療病毒感染的方法 |
| CA3231781A1 (en) * | 2021-09-18 | 2023-03-23 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof |
| US12637461B2 (en) | 2022-10-18 | 2026-05-26 | Pfizer Inc. | Compounds for the activation of AMPK |
| WO2024220173A1 (en) * | 2023-04-18 | 2024-10-24 | Genosco Inc. | Blood brain barrier penetrating selective inhibitors of rock2 protein kinases and uses thereof |
| EP4698528A1 (en) * | 2023-04-18 | 2026-02-25 | Genosco Inc. | Selective inhibitors of rock2 protein kinases and uses thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015025172A1 (en) * | 2013-08-22 | 2015-02-26 | Mark David Charles | 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use |
| EP3308786A1 (en) * | 2016-10-13 | 2018-04-18 | ETH Zurich | Fgfr regulaton for the treatment of viral infections |
| CN108699078A (zh) * | 2016-03-02 | 2018-10-23 | 吉利德阿波罗公司 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| US20190276440A1 (en) * | 2017-06-30 | 2019-09-12 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
| CN120548182A (zh) * | 2022-07-27 | 2025-08-26 | 格雷威顿生物科技有限公司 | 用于治疗病毒感染的rock2抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3470137A (en) * | 1967-02-14 | 1969-09-30 | Du Pont | Inter se copolymers of bicyclo(1.1.0)butanes |
| JP6593305B2 (ja) * | 2016-11-09 | 2019-10-23 | 株式会社村田製作所 | 二次電池用電解液、二次電池、電池パック、電動車両、電力貯蔵システム、電動工具および電子機器 |
| TWI804743B (zh) * | 2019-06-25 | 2023-06-11 | 大陸商北京泰德製藥股份有限公司 | 治療特發性肺纖維化的方法 |
| CN118772118A (zh) * | 2020-08-31 | 2024-10-15 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途 |
| CA3231781A1 (en) * | 2021-09-18 | 2023-03-23 | Beijing Tide Pharmaceutical Co., Ltd. | Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof |
| EP4434513A4 (en) * | 2021-11-16 | 2025-11-19 | Beijing Tide Pharmaceutical Co Ltd | NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS |
-
2022
- 2022-02-22 CA CA3209240A patent/CA3209240A1/en active Pending
- 2022-02-22 AU AU2022224669A patent/AU2022224669A1/en active Pending
- 2022-02-22 KR KR1020237031854A patent/KR20240009918A/ko active Pending
- 2022-02-22 CN CN202280030027.8A patent/CN117529320A/zh active Pending
- 2022-02-22 JP JP2023575684A patent/JP2024507414A/ja active Pending
- 2022-02-22 EP EP22757114.8A patent/EP4301132A4/en active Pending
- 2022-02-22 US US18/547,257 patent/US20240165116A1/en active Pending
- 2022-02-22 WO PCT/US2022/017312 patent/WO2022178420A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015025172A1 (en) * | 2013-08-22 | 2015-02-26 | Mark David Charles | 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use |
| CN108699078A (zh) * | 2016-03-02 | 2018-10-23 | 吉利德阿波罗公司 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| EP3308786A1 (en) * | 2016-10-13 | 2018-04-18 | ETH Zurich | Fgfr regulaton for the treatment of viral infections |
| US20190276440A1 (en) * | 2017-06-30 | 2019-09-12 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
| CN120548182A (zh) * | 2022-07-27 | 2025-08-26 | 格雷威顿生物科技有限公司 | 用于治疗病毒感染的rock2抑制剂 |
Non-Patent Citations (1)
| Title |
|---|
| KOCH JC, TÖNGES L, BARSKI E, MICHEL U, BÄHR M, LINGOR P.: "ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS", 《CELL DEATH DIS.》, vol. 15, no. 5, 15 May 2014 (2014-05-15), pages 1 - 12 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024507414A (ja) | 2024-02-19 |
| WO2022178420A1 (en) | 2022-08-25 |
| KR20240009918A (ko) | 2024-01-23 |
| CA3209240A1 (en) | 2022-08-25 |
| US20240165116A1 (en) | 2024-05-23 |
| EP4301132A4 (en) | 2025-03-26 |
| AU2022224669A1 (en) | 2023-09-28 |
| EP4301132A1 (en) | 2024-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240165116A1 (en) | Rock2 inhibitor for the treatment of viral infection | |
| RU2640485C2 (ru) | Комбинированное лечение рака | |
| US6384039B1 (en) | QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death | |
| AU2012321106B2 (en) | Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| KR101996245B1 (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| AU2008284364A1 (en) | Use of phosphatases to treat neuroblastomas and medulloblastomas | |
| JP2023109899A (ja) | 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法 | |
| CN111343986A (zh) | 用于治疗纤维化疾病的化合物及其药物组合物 | |
| HRP20040619A2 (en) | Combination of cytochome p<sub>450</sub> dependent protease inhibitors | |
| BR112021000938A2 (pt) | composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto | |
| TW201636049A (zh) | 組合癌症療法 | |
| US20240041861A1 (en) | Compositions and methods for treatment and prophylaxis of viral infections | |
| US20260007673A1 (en) | Rock2 inhibitors for the treatment of viral infections | |
| BRPI0616659A2 (pt) | droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose | |
| WO2014208354A1 (ja) | 炎症性疾患を治療又は予防するための医薬組成物 | |
| CN114072205A (zh) | 用tie-2激活剂治疗高血压的方法 | |
| CN118678960A (zh) | 用于治疗癌症的方法和组合物 | |
| JP2024518426A (ja) | 投与レジメン | |
| Ilango et al. | Roflumilast: an upcoming drug for curing asthma and COPD | |
| TW202327608A (zh) | 治療病毒感染的方法 | |
| HK40031991A (en) | Methods of treating and preventing graft versus host disease | |
| HK40063597A (en) | Methods of treating hypertension with activators of tie-2 | |
| HK40006418A (en) | Combinations and methods comprising a capsid assembly inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |